Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.

ABSTRACT: Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in severe disease. This pilot study was undertaken to inform feasibility and safety of further definitive studies. This was a prospective, interventional and randomized open label pilot trial in patients with severe COVID-19. Twenty COVID-19 patients received two 200 ml transfusions of convalescent patient CP over 24-h compared with 20 who received standard of care. The primary outcome was the requirement for ventilation (non-invasive or mechanical ventilation). The secondary outcomes were biochemical parameters and mortality at 28 days. The CP group were a higher risk group with higher ferritin levels (p < 0.05) though respiratory indices did not differ. The primary outcome measure was required in 6 controls

SUBMITTER: AlQahtani M 

PROVIDER: S-EPMC8113529 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature